{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:23:18Z","timestamp":1788232998613,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2012K001408"],"award-info":[{"award-number":["2012K001408"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jconrel.2013.05.031","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T11:36:48Z","timestamp":1370345808000},"page":"226-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan"],"prefix":"10.1016","volume":"170","author":[{"given":"Sukyung","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungjun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangyong","family":"Jon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2013.05.031_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1464-5491.2006.02071.x","article-title":"Incretins and other peptides in the treatment of diabetes","volume":"24","author":"Todd","year":"2007","journal-title":"Diabet. Med."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0017","article-title":"Biologic actions and therapeutic potential of the proglucagon-derived peptides","volume":"1","author":"Drucker","year":"2005","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0015","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","article-title":"Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration","volume":"356","author":"Gedulin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0025","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00125-005-0128-9","article-title":"Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs","volume":"49","author":"Simonsen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0030","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/bc700292v","article-title":"Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery","volume":"19","author":"Chae","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2008.09.091","article-title":"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice","volume":"133","author":"Jin","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0040","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.biomaterials.2010.12.044","article-title":"The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo","volume":"32","author":"Nguyen","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrd1067","article-title":"Challenges for the oral delivery of macromolecules","volume":"2","author":"Goldberg","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0168-3659(97)00136-3","article-title":"Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates","volume":"50","author":"Bernkop-Schnurch","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(02)00486-6","article-title":"Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo","volume":"249","author":"Pan","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2004.03.008","article-title":"Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption","volume":"97","author":"Morishita","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jconrel.2010.08.007","article-title":"Cyclodextrin complexed insulin encapsulated hydrogel microparticles: an oral delivery system for insulin","volume":"147","author":"Sajeesh","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/ar200234q","article-title":"pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications","volume":"45","author":"Sung","year":"2012","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0080","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/erd.09.43","article-title":"Challenges and advances in nanoparticle-based oral insulin delivery","volume":"6","author":"Ramesan","year":"2009","journal-title":"Expert Rev. Med. Devices"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jconrel.2009.08.014","article-title":"In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration","volume":"140","author":"Lee","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0090","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1021\/bc100093v","article-title":"A novel approach to oral delivery of insulin by conjugating with low molecular weight chitosan","volume":"21","author":"Lee","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0095","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1021\/jm800767c","article-title":"Conjugated chitosan as a novel platform for oral delivery of paclitaxel","volume":"51","author":"Lee","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jconrel.2004.10.012","article-title":"Influence of molecular weight on oral absorption of water soluble chitosans","volume":"102","author":"Chae","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0105","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1023\/A:1012160102740","article-title":"Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement","volume":"14","author":"Schipper","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0169-409X(01)00231-9","article-title":"Oral drug absorption enhancement by chitosan and its derivatives","volume":"52","author":"Thanou","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","article-title":"Evaluation of the clearance characteristics of bioadhesive systems in humans","volume":"178","author":"Soane","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0120","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.biomaterials.2007.01.005","article-title":"Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles","volume":"28","author":"Bravo-Osuna","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0125","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1016\/j.biomaterials.2010.05.042","article-title":"Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection","volume":"31","author":"Sonaje","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2010.01.024","article-title":"The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics","volume":"144","author":"Chae","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.addr.2004.02.007","article-title":"Potential applications of chitosan in veterinary medicine","volume":"56","author":"Senel","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jnci\/88.3-4.153","article-title":"Antibody-enzyme conjugates for cancer therapy","volume":"88","author":"Melton","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2003.05.001","article-title":"Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer\/GSH systems","volume":"93","author":"Bernkop-Schnurch","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0150","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.addr.2006.09.017","article-title":"Freeze-drying of nanoparticles: formulation, process and storage considerations","volume":"58","author":"Abdelwahed","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0155","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jps.20364","article-title":"Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and\/or immobilization in a glassy matrix?","volume":"94","author":"Chang","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0160","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/0250-474X.42967","article-title":"Protein and peptide drug delivery: oral approaches","volume":"70","author":"Shaji","year":"2008","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","article-title":"Emerging trends in oral delivery of peptide and protein drugs","volume":"20","author":"Mahato","year":"2003","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2013.05.031_bb0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCULATIONAHA.107.735795","article-title":"New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond","volume":"117","author":"Inzucchi","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2013.05.031_bb0175","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1016\/j.biomaterials.2010.01.091","article-title":"Long acting hyaluronate\u2014exendin 4 conjugate for the treatment of type 2 diabetes","volume":"31","author":"Kong","year":"2010","journal-title":"Biomaterials"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913003210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365913003210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:27:43Z","timestamp":1759159663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365913003210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0168365913003210"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.031","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}